Mitsubishi UFJ Asset Management’s Biogen BIIB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$61.3M Buy
334,413
+14,504
+5% +$2.67M 0.04% 339
2025
Q4
$56.9M Buy
319,909
+12,530
+4% +$2.05M 0.04% 336
2025
Q3
$43.1M Buy
307,379
+13,110
+4% +$1.77M 0.03% 389
2025
Q2
$37M Buy
294,269
+20,721
+8% +$2.58M 0.03% 408
2025
Q1
$37.4M Buy
273,548
+27,734
+11% +$3.96M 0.03% 373
2024
Q4
$37.4M Buy
245,814
+22,182
+10% +$3.74M 0.04% 364
2024
Q3
$43.3M Buy
223,632
+20,536
+10% +$4.3M 0.05% 313
2024
Q2
$47.1M Buy
203,096
+23,677
+13% +$5.15M 0.06% 273
2024
Q1
$38.7M Buy
179,419
+29,991
+20% +$7.02M 0.05% 288
2023
Q4
$39.4M Buy
149,428
+7,683
+5% +$1.89M 0.07% 237
2023
Q3
$36.4M Buy
141,745
+13,974
+11% +$3.74M 0.07% 226
2023
Q2
$36.4M Buy
127,771
+8,195
+7% +$2.44M 0.08% 215
2023
Q1
$33.2M Buy
119,576
+8,107
+7% +$2.24M 0.08% 210
2022
Q4
$30.4M Buy
111,469
+13,781
+14% +$3.89M 0.08% 208
2022
Q3
$26.1M Buy
97,688
+7,291
+8% +$1.55M 0.08% 199
2022
Q2
$18.4M Buy
90,397
+5,831
+7% +$1.19M 0.08% 245
2022
Q1
$17.8M Buy
84,566
+6,801
+9% +$1.48M 0.07% 278
2021
Q4
$19M Buy
77,765
+10,774
+16% +$2.77M 0.08% 264
2021
Q3
$19M Buy
66,991
+7,095
+12% +$2.33M 0.09% 222
2021
Q2
$20.7M Buy
59,896
+6,239
+12% +$1.89M 0.11% 188
2021
Q1
$15M Buy
53,657
+6,117
+13% +$1.65M 0.1% 213
2020
Q4
$11.6M Buy
47,540
+710
+2% +$183K 0.09% 238
2020
Q3
$13.3M Buy
46,830
+2,778
+6% +$775K 0.12% 170
2020
Q2
$11.8M Buy
44,052
+4,214
+11% +$1.27M 0.13% 149
2020
Q1
$12.6M Sell
39,838
-1,241
-3% -$377K 0.19% 105
2019
Q4
$11.9M Buy
41,079
+5,026
+14% +$1.39M 0.16% 141
2019
Q3
$8.39M Buy
36,053
+699
+2% +$163K 0.14% 155
2019
Q2
$8.27M Buy
35,354
+6,497
+23% +$1.5M 0.14% 145
2019
Q1
$6.82M Buy
28,857
+1,760
+6% +$554K 0.14% 138
2018
Q4
$8.32M Sell
27,097
-3,277
-11% -$1.05M 0.21% 103
2018
Q3
$10.7M Sell
30,374
-1,850
-6% -$637K 0.22% 94
2018
Q2
$9.35M Sell
32,224
-9,327
-22% -$2.62M 0.21% 98
2018
Q1
$11.4M Buy
41,551
+6,711
+19% +$2.08M 0.26% 81
2017
Q4
$11.8M Buy
34,840
+302
+0.9% +$96.9K 0.26% 81
2017
Q3
$10.8M Sell
34,538
-1,122
-3% -$332K 0.25% 84
2017
Q2
$9.68M Sell
35,660
-33,952
-49% -$8.98M 0.24% 91
2017
Q1
$19M Buy
69,612
+3,518
+5% +$995K 0.43% 51
2016
Q4
$19.3M Sell
66,094
-5,419
-8% -$1.61M 0.47% 49
2016
Q3
$22.4M Buy
71,513
+265
+0.4% +$78.5K 0.56% 47
2016
Q2
$17.2M Buy
71,248
+5,465
+8% +$1.44M 0.45% 61
2016
Q1
$17.1M Buy
65,783
+5,402
+9% +$1.43M 0.46% 58
2015
Q4
$18.5M Sell
60,381
-20,216
-25% -$5.81M 0.53% 50
2015
Q3
$23.5M Buy
80,597
+14,900
+23% +$4.92M 0.74% 31
2015
Q2
$26.5M Sell
65,697
-8,876
-12% -$3.56M 0.81% 25
2015
Q1
$31.5M Buy
74,573
+12,626
+20% +$4.98M 0.93% 21
2014
Q4
$21.2M Buy
61,947
+2,728
+5% +$883K 0.65% 35
2014
Q3
$19.6M Sell
59,219
-13,403
-18% -$4.42M 0.59% 41
2014
Q2
$22.9M Buy
72,622
+15,417
+27% +$4.64M 0.59% 40
2014
Q1
$17.5M Buy
57,205
+3,187
+6% +$1.01M 0.47% 48
2013
Q4
$15M Sell
54,018
-14,622
-21% -$3.78M 0.43% 49
2013
Q3
$16.5M Buy
68,640
+8,190
+14% +$1.83M 0.43% 50
2013
Q2
$13M Buy
+60,450
New +$12.9M 0.37% 55

Other funds holding BIIB

Mitsubishi UFJ Asset Management's BIIB Position: Q1 2026 in Review

Mitsubishi UFJ Asset Management increased its Biogen (BIIB) stake by 4.5% in Q1 2026, buying an estimated $2.67M and bringing the position to 334,413 shares worth $61.3M. The position accounts for 0.04% of the portfolio, ranked #339.

Mitsubishi UFJ Asset Management first reported a position in BIIB in Q2 2013 and has held it in 52 quarters since. 1,003 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.

  • Mitsubishi UFJ Asset Management held 334,413 shares of Biogen worth $61.3M as of Q1 2026.
  • Mitsubishi UFJ Asset Management bought 14,504 Biogen shares in Q1 2026, an estimated $2.67M.
  • Biogen made up 0.04% of Mitsubishi UFJ Asset Management's portfolio in Q1 2026, its #339 holding.
  • Mitsubishi UFJ Asset Management first reported a position in Biogen in Q2 2013 and has held it in 52 quarters since.
  • 1,003 funds tracked by Wall St. Rank held Biogen as of Q1 2026.

Based on Mitsubishi UFJ Asset Management's 13F filing for Q1 2026, filed 12 May 2026.